IP Library Granted Patent US 12,628,854
Granted Patent B2
US 12,628,854 · App. 17/772,698 · Granted May 19, 2026

Delayed release softgel capsules in higher pH environment

Inventors: Karunakar Sukuru (St. Petersburg, FL); Qi Fang (St. Petersburg, FL); Haitao Li (St. Petersburg, FL)
Assignee: R.P. Scherer Technologies, LLC
A23L29/231A23L29/272A23L29/273A23L29/284A23L33/29A23P10/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,628,854
App. No.
17/772,698
Granted
May 19, 2026
Kind
B2
Abstract

Disclosed in certain embodiments is a delayed release softgel capsules comprise a fill material that is encapsulated in a pH dependent shell composition, the pH dependent shell composition including pectin and gellan gum. Also disclosed are methods of preparing any of the delayed release softgel capsules described herein and methods of use thereof.

Claims (21)

1 . A delayed release softgel capsule comprising:

(a) a fill material; and

(b) a shell composition,

wherein the fill material comprises at least one active agent, and

wherein the shell composition comprises gelatin and a pH dependent polymer comprising pectin and gellan gum, wherein a ratio of the pectin to gellan gum is from about 10:1 to about 24:1, and about 0.01 wt % to about 2 wt % of dextrose, wherein the shell composition does not rupture at a pH of 4 at 15 minutes, 30 minutes, 45 minutes or 60 minutes when measured with a USP Apparatus II with paddles at 50 RPM, 900 ml 0.1N HCL acidic media adjusted to pH with phosphate buffer.

2 . The delayed release softgel capsule of claim 1 , wherein the shell composition does not rupture at a pH of 5 at 15 minutes, 30 minutes, 45 minutes or 60 minutes when measured with a USP Apparatus II with paddles at 50 RPM, 900 ml 0.1N HCL acidic media adjusted to pH with phosphate buffer.

3 . The delayed release softgel capsule of claim 1 , wherein the shell composition does not rupture at a pH of between 5 and 6 at 15 minutes, 30 minutes, 45 minutes or 60 minutes when measured with a USP Apparatus II with paddles at 50 RPM, 900 ml 0.1N HCL acidic media adjusted to pH with phosphate buffer.

4 . The delayed release softgel capsule of claim 1 , wherein the shell composition does not rupture at a pH of between 6 and 7 at 15 minutes, 30 minutes, 45 minutes, or 60 minutes, when measured with a USP Apparatus II with paddles at 50 RPM, 900 ml 0.1N HCL acidic media adjusted to pH with phosphate buffer.

5 . The delayed release softgel capsule of claim 1 , wherein the shell composition does not rupture at a pH of between 7 and 8 at 15 minutes, 30 minutes, 45 minutes, or 60 minutes when measured with a USP Apparatus II with paddles at 50 RPM, 900 ml 0.1N HCL acidic media adjusted to pH with phosphate buffer.

6 . The delayed release softgel capsule of claim 1 , wherein the shell composition does not rupture at a pH of between 8 and 8.4 at 15 minutes, 30 minutes, 45 minutes, or 60 minutes when measured with a USP Apparatus II with paddles at 50 RPM, 900 ml 0.1N HCL acidic media adjusted to pH with phosphate buffer.

7 . The delayed release softgel capsule of claim 1 , wherein the shell composition is derived from a wet mass comprising 0.1 to 5% gellan gum.

8 . The delayed release softgel capsule of claim 7 , wherein the wet mass further comprises from about 2% to about 10% pectin.

9 . The delayed release softgel capsule of claim 1 , wherein the shell composition comprises about 40 wt % to about 80 wt % of a gelatin, based on total weight of the dry shell composition.

10 . The delayed release softgel capsule of claim 1 , wherein the shell composition comprises about 0.1 wt % to about 10 wt % or about 0.4 wt % to about 5 wt % of gellan gum, based on total weight of the dry shell composition.

11 . The delayed release softgel capsule of claim 1 , wherein the shell composition comprises about 0.1 wt % to about 10 wt % or about 2 wt % to about 20 wt % of pectin, based on total weight of the dry shell composition.

12 . A process for preparing a delayed release softgel capsule according to claim 1 comprising the steps of:

preparing a fill material comprising an active agent; and

encapsulating the fill material with a shell composition, wherein the shell composition comprises gelatin and a pH dependent polymer comprising pectin and gellan gum, wherein the shell composition does not rupture at a pH of 4 at 15 minutes, 30 minutes, 45 minutes or 60 minutes when measured with a USP Apparatus II with paddles at 50 RPM, 900 ml 0.1N HCL acidic media adjusted to pH with phosphate buffer.

13 . A method of delivering an active agent to a target location within the gastrointestinal tract, the method comprising administering to a subject the delayed release softgel capsule according to claim 1 ,

wherein the shell composition of the delayed release softgel capsule dissolves/disintegrates in a pH of the target location in up to about 120 minutes, in up to about 90 minutes, in up to about 60 minutes, in up to about 30 minutes, or in up to about 15 minutes, and

wherein the shell composition of the delayed release softgel capsule does not dissolve/disintegrate or does not substantially dissolve/disintegrate in a pH that is lower than the pH of the target location in up to about 120 minutes, in up to about 90 minutes, in up to about 60 minutes, in up to about 30 minutes, or in up to about 15 minutes.

Assignments (2)
SECURITY INTEREST Recorded Dec 19, 2024
From: CATALENT CTS (KANSAS CITY), LLC; REDWOOD BIOSCIENCE, INC.; R.P. SCHERER TECHNOLOGIES, LLC; CATALENT WELLNESS, LLC; CATALENT PHARMA SOLUTIONS, INC.; CATALENT WELLNESS NEW JERSEY, LLC; CATALENT MARYLAND, INC.; CATALENT GREENVILLE, INC.; CATALENT MICRON TECHNOLOGIES, INC.; CATALENT SAN DIEGO, INC.; CATALENT WELLNESS VIRGINIA, LLC; CATALENT USA PACKAGING, LLC; CATALENT PHARMA SOLUTIONS, LLC
To: ARES CAPITAL CORPORATION, AS COLLATERAL AGENT
Reel/Frame 069743/0458 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 9, 2023
From: SUKURU, KARUNAKAR; FANG, QI; LI, HAITAO
To: R.P. SCHERER TECHNOLOGIES, LLC
Reel/Frame 063578/0008 →
Continuity (2)
Provisional Application 62926681 · Oct 28, 2019
Related Publication 20220400724A1 · Dec 22, 2022
References Cited (42)
US 7041315B2 · Scott et al. · 2006 [cited by applicant]
US 10226432B2 · Teles et al. · 2019 [cited by applicant]
US 20020114832A1 · Herrmann · 2002 [cited by examiner]
US 20030175335A1 · Scott · 2003 [cited by applicant]
US 20080299199A1 · Bar-Shalom et al. · 2008 [cited by applicant]
US 20100158840A1 · Hiramoto · 2010 [cited by examiner]
US 20100158958A1 · Chidambaram · 2010 [cited by applicant]
US 20130280323A1 · Fang · 2013 [cited by examiner]
US 20150004226A1 · Baes et al. · 2015 [cited by applicant]
US 20150118298A1 · Zhang et al. · 2015 [cited by applicant]
US 20170119680A1 · McGuffy et al. · 2017 [cited by applicant]
US 20170119711A1 · Hu et al. · 2017 [cited by applicant]
US 20170209384A1 · Watanabe et al. · 2017 [cited by applicant]
US 20170296474A1 · Masuda · 2017 [cited by applicant]
US 20180169051A1 · Zhang · 2018 [cited by examiner]
US 20180235891A1 · Fang et al. · 2018 [cited by applicant]
US 20180353432A1 · Carucci et al. · 2018 [cited by applicant]
CN 101919827A · 2010 [cited by applicant]
CN 103483604A · 2014 [cited by applicant]
CO 2021018071A2 · 2022 [cited by applicant]
EA 7563B1 · 2006 [cited by applicant]
EP 3178473A1 · 2017 [cited by applicant]
JP H0427352A · 1992 [cited by applicant]
JP 2009028544A1 · 2009 [cited by examiner]
WO 0217886A1 · 2002 [cited by applicant]
WO 2004030658A1 · 2004 [cited by applicant]
WO 2006016577A1 · 2006 [cited by applicant]
WO 2007075475A2 · 2007 [cited by applicant]
WO 2013093630A2 · 2013 [cited by applicant]
WO 2017097612A1 · 2017 [cited by applicant]
WO 2019178444A1 · 2019 [cited by applicant]
Davie Mabey, “Epidemiology of Sexually Transmitted Infections: Worldwide”, Epidemilogy and Sexual Behaviour, 42:6, 2014 Elsevier Ltd., 4 pages. [cited by applicant]
Tran et al., Survival Comparision between Glioblastoma Multiforme and Other Incurable Cancers, Journal of Clinical Neuroscience 18 (2010) , 5 pages. [cited by applicant]
Miguel Lopez-Lazaro, “The Migration Ability of Stem Cells can Explain the Existence of Cancer of Unknown Primary Site. Rethinking Metastasis”, Oncoscience, 2015, vol. 2, No. 5, 1 page. [cited by applicant]
Peter B. Dirks, “Brain Tumor Stem Cells: Bringing Order to the Chaos of Brian Cancer”, Journal of Clinical Oncology, vol. 26, No. 17, Jun. 10, 2008, 1 page. [cited by applicant]
Choudhary, “Different Types of Dissolution Apparatus”, Pharmaceutical Guildlines, 2017, 2 pages. [cited by applicant]
International Search Report and Written Opinon for PCT/US2020/057522 mailed Jan. 26, 2021, 9 pages. [cited by applicant]
Extended European Search Report for European Application No. 20880928.5, mailed Nov. 6, 2023, 7 Pages. [cited by applicant]
Badipatla, Viswesvararao “Disintegration of Tablets and Capsules Measured by Isothermal Thermal Mechanical Analysis and Macrophotography,” Bachelor of Science in Pharmacy, May 2007, ETD Archive, 2010, pp. 4, 13, retriev… [cited by applicant]
Espitia P.J.P., et al., “Edible Films From Pectin: Physical-mechanical And Antimicrobial Properties—A Review,” Food Hydrocolloids, Mar. 2014, vol. 35, pp. 287-296. [cited by applicant]
Examination Report for Colombian Patent Application No. 20220007168, mailed Feb. 24, 2025, 6 Pages. [cited by applicant]
Office Action for Colombian Patent Application No. CO2022007168, mailed Oct. 31, 2025, 20 Pages. [cited by applicant]